These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
564 related articles for article (PubMed ID: 30760114)
1. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy. Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114 [TBL] [Abstract][Full Text] [Related]
2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer]. Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919 [No Abstract] [Full Text] [Related]
3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection]. Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920 [No Abstract] [Full Text] [Related]
4. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator. Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105 [No Abstract] [Full Text] [Related]
5. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study. Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628 [TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590 [TBL] [Abstract][Full Text] [Related]
8. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin. Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386 [TBL] [Abstract][Full Text] [Related]
9. Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Chen L; Zuo Y; Zhu L; Zhang Y; Li S; Ma F; Han Y; Song H; Xue Y Onco Targets Ther; 2017; 10():2569-2580. PubMed ID: 28553122 [TBL] [Abstract][Full Text] [Related]
10. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer]. Wan Y; Hui H; Wang X; Wu J; Sun S Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090 [TBL] [Abstract][Full Text] [Related]
13. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156 [TBL] [Abstract][Full Text] [Related]
14. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study. Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706 [No Abstract] [Full Text] [Related]
16. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage. Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475 [TBL] [Abstract][Full Text] [Related]
17. Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy. Chen L; Hao Y; Zhu L; Li S; Zuo Y; Zhang Y; Song H; Xue Y Onco Targets Ther; 2017; 10():4007-4016. PubMed ID: 28860808 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Kim EJ; Kim M; Seo S; Kim MJ; Kim MJ; Park SR Anticancer Res; 2021 Jan; 41(1):391-402. PubMed ID: 33419836 [TBL] [Abstract][Full Text] [Related]
19. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102 [TBL] [Abstract][Full Text] [Related]
20. Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. Huang Z; Liu Y; Yang C; Li X; Pan C; Rao J; Li N; Liao W; Lin L BMC Cancer; 2018 May; 18(1):515. PubMed ID: 29720123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]